Sarepta Therapeutics (SRPT) executive compensation, 2026 proxy

Douglas S. Ingram, Chief Executive Officer, was paid $7.8M in 2025, up 296% from $2M the year before. The CEO-to-median-employee pay ratio was 25:1, on median employee pay of $308,335.

Filed
April 24, 2026
Annual meeting
June 4, 2026
Pay year
2025
Named executives
6
CEO total pay
$7.8M+296% vs prior year
CEO to median employee
25:1median $308,335
CEO pay in equity
77%$6M in awards
Prior say-on-pay support
97%of votes cast
CEO Total Compensation
$7,840,666Fiscal year 2025
CEO to Median Employee Pay Ratio
25:1Based on median employee pay of $308,335
Say-on-Pay Support
97%Previous annual meeting support

How Ingram was paid

$7.8M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary15%Stock awards77%Non-equity incentive8%All other compensation0%

Named executive officers

ExecutiveTotal
Douglas S. IngramChief Executive Officer$7,840,666
Ryan H. WongExecutive Vice President, Chief Financial Officer$3,211,867
Ian M. EstepanPresident, Chief Operating Officer$4,444,392
Louise Rodino-Klapac, Ph.D.President, Research and Development and Technical Operations$4,456,270
Cristin L. RothfussExecutive Vice President, General Counsel$4,233,623
Dallan MurrayFormer Executive Vice President, Chief Customer Officer$2,742,790

What changed and why

  • $7.8MCEO total compensation increased to $7,840,666 in fiscal year 2025 compared to prior years.
  • 50%The company executed a 50% reduction in annual incentive bonus targets following program recalibration.
  • An immaterial financial restatement triggered a clawback analysis, which resulted in no recovery of compensation.
  • 97%Stockholders approved the previous say-on-pay proposal with approximately 97% support at the 2025 annual meeting.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.